NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: V
Post# of 111
(Total Views: 261)
Posted On: 03/22/2019 6:55:01 PM
NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) Subsidiary Receives Health Canada Approval for Vanluven Road Facility Expansion
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) on Thursday announced that its wholly-owned subsidiary, ABcann Medicinals Inc., received approval from Health Canada to commence cultivation in the expansion of its Vanluven Road facility in Napanee. The expansion includes production and product development space built to GMP standards and doubles the company’s Ontario cultivation capacity. Cultivation in the expanded area will begin immediately. In addition, the company has incorporated a supercritical CO2 extraction suite for production of concentrates into the facility, which is expected to be brought on-line mid-2019. “The GMP certification of our Vanluven expansion, expected later this year, will enable us to service the growing international medical cannabis market. We are excited to build on our success by introducing new high-margin, value-added products which leverage our increased production capabilities and tap into the user insights gained from our vast Harvest Medicine Clinic patient network,” VIVO CEO Barry Fishman stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) on Thursday announced that its wholly-owned subsidiary, ABcann Medicinals Inc., received approval from Health Canada to commence cultivation in the expansion of its Vanluven Road facility in Napanee. The expansion includes production and product development space built to GMP standards and doubles the company’s Ontario cultivation capacity. Cultivation in the expanded area will begin immediately. In addition, the company has incorporated a supercritical CO2 extraction suite for production of concentrates into the facility, which is expected to be brought on-line mid-2019. “The GMP certification of our Vanluven expansion, expected later this year, will enable us to service the growing international medical cannabis market. We are excited to build on our success by introducing new high-margin, value-added products which leverage our increased production capabilities and tap into the user insights gained from our vast Harvest Medicine Clinic patient network,” VIVO CEO Barry Fishman stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VIVO Cannabis Inc. (VVCIF) Stock Research Links
Scroll down for more posts ▼